Rose Louise, Adhikari Neill Kj, Leasa David, Fergusson Dean A, McKim Douglas
Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, 155 College St, Toronto, ON, Canada, M5T 1P8.
Interdepartmental Division of Critical Care, University of Toronto, Toronto, ON, Canada.
Cochrane Database Syst Rev. 2017 Jan 11;1(1):CD011833. doi: 10.1002/14651858.CD011833.pub2.
There are various reasons why weaning and extubation failure occur, but ineffective cough and secretion retention can play a significant role. Cough augmentation techniques, such as lung volume recruitment or manually- and mechanically-assisted cough, are used to prevent and manage respiratory complications associated with chronic conditions, particularly neuromuscular disease, and may improve short- and long-term outcomes for people with acute respiratory failure. However, the role of cough augmentation to facilitate extubation and prevent post-extubation respiratory failure is unclear.
Our primary objective was to determine extubation success using cough augmentation techniques compared to no cough augmentation for critically-ill adults and children with acute respiratory failure admitted to a high-intensity care setting capable of managing mechanically-ventilated people (such as an intensive care unit, specialized weaning centre, respiratory intermediate care unit, or high-dependency unit).Secondary objectives were to determine the effect of cough augmentation techniques on reintubation, weaning success, mechanical ventilation and weaning duration, length of stay (high-intensity care setting and hospital), pneumonia, tracheostomy placement and tracheostomy decannulation, and mortality (high-intensity care setting, hospital, and after hospital discharge). We evaluated harms associated with use of cough augmentation techniques when applied via an artificial airway (or non-invasive mask once extubated/decannulated), including haemodynamic compromise, arrhythmias, pneumothorax, haemoptysis, and mucus plugging requiring airway change and the type of person (such as those with neuromuscular disorders or weakness and spinal cord injury) for whom these techniques may be efficacious.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 4, 2016), MEDLINE (OvidSP) (1946 to April 2016), Embase (OvidSP) (1980 to April 2016), CINAHL (EBSCOhost) (1982 to April 2016), and ISI Web of Science and Conference Proceedings. We searched the PROSPERO and Joanna Briggs Institute databases, websites of relevant professional societies, and conference abstracts from five professional society annual congresses (2011 to 2015). We did not impose language or other restrictions. We performed a citation search using PubMed and examined reference lists of relevant studies and reviews. We contacted corresponding authors for details of additional published or unpublished work. We searched for unpublished studies and ongoing trials on the International Clinical Trials Registry Platform (apps.who.int/trialsearch) (April 2016).
We included randomized and quasi-randomized controlled trials that evaluated cough augmentation compared to a control group without this intervention. We included non-randomized studies for assessment of harms. We included studies of adults and of children aged four weeks or older, receiving invasive mechanical ventilation in a high-intensity care setting.
Two review authors independently screened titles and abstracts identified by our search methods. Two review authors independently evaluated full-text versions, independently extracted data and assessed risks of bias.
We screened 2686 citations and included two trials enrolling 95 participants and one cohort study enrolling 17 participants. We assessed one randomized controlled trial as being at unclear risk of bias, and the other at high risk of bias; we assessed the non-randomized study as being at high risk of bias. We were unable to pool data due to the small number of studies meeting our inclusion criteria and therefore present narrative results rather than meta-analyses. One trial of 75 participants reported that extubation success (defined as no need for reintubation within 48 hours) was higher in the mechanical insufflation-exsufflation (MI-E) group (82.9% versus 52.5%, P < 0.05) (risk ratio (RR) 1.58, 95% confidence interval (CI) 1.13 to 2.20, very low-quality evidence). No study reported weaning success or reintubation as distinct from extubation success. One trial reported a statistically significant reduction in mechanical ventilation duration favouring MI-E (mean difference -6.1 days, 95% CI -8.4 to -3.8, very low-quality evidence). One trial reported mortality, with no participant dying in either study group. Adverse events (reported by two trials) included one participant receiving the MI-E protocol experiencing haemodynamic compromise. Nine (22.5%) of the control group compared to two (6%) MI-E participants experienced secretion encumbrance with severe hypoxaemia requiring reintubation (RR 0.25, 95% CI 0.06 to 1.10). In the lung volume recruitment trial, one participant experienced an elevated blood pressure for more than 30 minutes. No participant experienced new-onset arrhythmias, heart rate increased by more than 25%, or a pneumothorax.For outcomes assessed using GRADE, we based our downgrading decisions on unclear risk of bias, inability to assess consistency or publication bias, and uncertainty about the estimate of effect due to the limited number of studies contributing outcome data.
AUTHORS' CONCLUSIONS: The overall quality of evidence on the efficacy of cough augmentation techniques for critically-ill people is very low. Cough augmentation techniques when used in mechanically-ventilated critically-ill people appear to result in few adverse events.
撤机和拔管失败有多种原因,但无效咳嗽和分泌物潴留可能起重要作用。咳嗽增强技术,如肺容量复张或手动及机械辅助咳嗽,用于预防和管理与慢性疾病相关的呼吸并发症,特别是神经肌肉疾病,可能改善急性呼吸衰竭患者的短期和长期预后。然而,咳嗽增强在促进拔管和预防拔管后呼吸衰竭中的作用尚不清楚。
我们的主要目的是确定与未使用咳嗽增强技术相比,使用咳嗽增强技术对入住能够管理机械通气患者的高强度护理环境(如重症监护病房、专业撤机中心、呼吸中级护理病房或高依赖病房)的急性呼吸衰竭危重症成人和儿童进行拔管的成功率。次要目的是确定咳嗽增强技术对再次插管、撤机成功、机械通气和撤机持续时间、住院时间(高强度护理环境和医院)、肺炎、气管切开术置管和气管切开术拔管以及死亡率(高强度护理环境、医院和出院后)的影响。我们评估了通过人工气道(或拔管/拔管后使用无创面罩)应用咳嗽增强技术相关的危害,包括血流动力学不稳定、心律失常、气胸、咯血以及需要更换气道的黏液阻塞,以及这些技术可能有效的人群类型(如神经肌肉疾病或无力以及脊髓损伤患者)。
我们检索了Cochrane对照试验中央注册库(CENTRAL;2016年第4期)、MEDLINE(OvidSP)(1946年至2016年4月)、Embase(OvidSP)(1980年至2016年4月)、CINAHL(EBSCOhost)(1982年至2016年4月)以及ISI科学网和会议论文集。我们检索了PROSPERO和乔安娜·布里格斯研究所数据库、相关专业学会网站以及五个专业学会年会(2011年至2015年)的会议摘要。我们未施加语言或其他限制。我们使用PubMed进行了引文检索,并检查了相关研究和综述的参考文献列表。我们联系了通讯作者以获取其他已发表或未发表工作的详细信息。我们在国际临床试验注册平台(apps.who.int/trialsearch)(2016年4月)上搜索了未发表的研究和正在进行的试验。
我们纳入了评估咳嗽增强与未进行此干预的对照组相比的随机和半随机对照试验。我们纳入了非随机研究以评估危害。我们纳入了在高强度护理环境中接受有创机械通气的成人和四周及以上儿童的研究。
两位综述作者独立筛选通过我们检索方法识别的标题和摘要。两位综述作者独立评估全文版本,独立提取数据并评估偏倚风险。
我们筛选了2686条引文,纳入了两项试验(95名参与者)以及一项队列研究(17名参与者)。我们将一项随机对照试验评估为偏倚风险不明确,另一项为高偏倚风险;我们将非随机研究评估为高偏倚风险。由于符合我们纳入标准的研究数量较少,我们无法汇总数据,因此呈现叙述性结果而非荟萃分析。一项75名参与者的试验报告称,机械吸气 - 呼气(MI - E)组的拔管成功率(定义为48小时内无需再次插管)更高(82.9%对52.5%,P < 0.05)(风险比(RR)1.58,95%置信区间(CI)1.13至2.20,极低质量证据)。没有研究将撤机成功或再次插管与拔管成功区分开来报告。一项试验报告称,有利于MI - E的机械通气持续时间有统计学意义的缩短(平均差异 - 6.1天,95% CI - 8.4至 - 3.8,极低质量证据)。一项试验报告了死亡率,两个研究组均无参与者死亡。不良事件(两项试验报告)包括一名接受MI - E方案的参与者出现血流动力学不稳定。对照组的9名(22.5%)参与者与MI - E组的2名(6%)参与者出现分泌物阻塞并伴有严重低氧血症需要再次插管(RR 0.25,95% CI 0.06至1.10)。在肺容量复张试验中,一名参与者血压升高超过30分钟。没有参与者出现新发心律失常、心率增加超过25%或气胸。对于使用GRADE评估的结果,我们基于偏倚风险不明确、无法评估一致性或发表偏倚以及由于提供结果数据的研究数量有限导致效应估计的不确定性来做出降级决定。
关于咳嗽增强技术对危重症患者疗效的证据总体质量非常低。在机械通气的危重症患者中使用咳嗽增强技术似乎导致很少的不良事件。